~theguardian-world | Bookmarks (1)

Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmakerAstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a...